tbuckley/cabot-search huggingface dataset:
SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.
Authors: Davendra Sohal, Danika L. Lew, Syed A. Ahmad, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang-Gillam, James Lloyd Wade, Katherine A Guthrie, Andrew M. Lowy, Philip Agop Philip, Howard S. Hochster
Journal: Journal of Clinical Oncology (2019)

4137 Background: Clinical outcomes after curative therapy of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. For early control of systemic disease with aggressive perioperative chemotherapy (CTx), we conducted a prospective trial in the National Clinical Trials Network (NCTN) setting. Methods: S1505 was a randomized phase II trial of periop (12 weeks pre-, 12 weeks post-op) CTx with either mFOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin – without bolus 5-FU and leucovorin; Arm 1), or gemcitabine/nab-paclitaxel (Arm 2). Eligibility required adult patients with ECOG PS 0 or 1, confirmed tissue diagnosis of PDA, and resectable disease: no involvement of the celiac, common hepatic, or superior mesenteric arteries (and, if present, variants); &lt; 180° interface between tumor and vessel wall, of the portal or superior mesenteric veins; patent portal vein/splenic vein confluence; no metastases. Primary outcome is 2-year overall survival (OS), using a “pick the winner” design; for 100 eligible patients, accrual up to 150 patients was planned, to account for cases deemed ineligible at central radiology review. Results: From 2015 to 2018, 147 patients were enrolled; 74 to Arm 1; 73 to Arm 2. At central radiology review, 42/147 (29%) were ineligible; of these, 15 (36%) had venous involvement ≥180°, 22 (52%) had arterial involvement, 28 (67%) had distant disease. One patient had distal cholangiocarcinoma (ineligible); one withdrew consent after randomization. Eligible patients (n = 103) had median age 64 years; males 58%; whites 89%; PS 0 64%. Of 103, 99 (96%) started and 86 (83%) completed preop CTx. There was one death due to sepsis and 61 additional patients experienced grade 3/4 toxicities. To date, 76 of 99 (77%) patients went to surgery and 72 (73%) underwent resection. Conclusions: This is the first-ever NCTN study of periop CTx for resectable PDA. Accrual was brisk, establishing feasibility. Ineligible cases after central radiology review highlight quality control and physician education imperatives for neoadjuvant PDA trials. Preop CTx safety and resection rates are encouraging. Follow up for OS is ongoing. Clinical trial information: NCT02562716.
Abstract LB-110: Proteasome addiction a new therapeutic opportunity to treat PTEN-deficient brain tumors
Authors: Jorge A. Benitez, Darren Finlay, Alexandre Rosa-Campos, Jianhui Ma, Tomoyuki Koga, Kristiina Vuori, Frank Furnari
Journal: Cancer Research (2019)

Abstract One of the most common genetic alterations in glioblastoma (30-40%) occurs in the tumor suppressor gene PTEN (phosphatase and tensin homolog), where loss of function has been mechanistically linked to increased tumor cell invasion, and to a lack of radio- and chemo-therapy response. To identify new drug compounds that target PTEN-deficient brain tumors we performed a high throughput drug screening using patient-derived GBM spheres and found that PTEN-deficient samples were highly sensitive to proteasome inhibitors. We confirmed PTEN dependency to proteasome inhibition by genetically overexpressing or deleting PTEN in GBM cells and established that the drug inhibition response relied on PTEN enzymatic activity. Additionally, proteasome inhibition specifically suppressed tumor growth and increased survival of mice orthotopically engrafted with human PTEN-null glioblastoma cancer stem cells. Mechanistically, we determined that PTEN-deficient cells were more sensitive to proteasome inhibition due to an increase in protein synthesis rate and loss of autophagy activity associated with activation of the PI3K/mTOR pathway. Finally, integrated in silico analysis of the Samsung Medical Center dataset corroborated that samples with PTEN/EGFR/PI3K alterations were significantly more sensitive to Carfilzomib, an FDA-approved proteasome inhibitor. This study reveals that PTEN-deficient cells are "proteasome addictive" and opens a new therapeutic opportunity to treat glioblastoma PTEN-deficient patients. Citation Format: Jorge A. Benitez, Darren Finlay, Alexandre Rosa-Campos, Jianhui Ma, Tomoyuki Koga, Kristiina Vuori, Frank Furnari. Proteasome addiction a new therapeutic opportunity to treat PTEN-deficient brain tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-110.
Hepatology Highlights
Authors: Russell Rosenblatt, Nicholas Russo, Robert S. Brown, Nicole T. Shen, Robert E. Schwartz, Rachel Niec, Shawn Shah, Joseph F. Pisa, Vikas Gupta, Ashley Wu, Zaid H. Tafesh
Journal: Hepatology (2018)

Rosenblatt, Russell; Russo, Nicholas; Brown, Robert S. Jr.; Shen, Nicole T.; Schwartz, Robert E.; Niec, Rachel; Shah, Shawn; Pisa, Joseph F.; Gupta, Vikas; Wu, Ashley; Tafesh, Zaid H. Author Information
Abstract IA17: Molecular characterization of mucinous ovarian carcinoma.
Authors: Douglas A. Levine, Brooke Schlappe
Journal: Clinical Cancer Research (2016)

Abstract Mucinous ovarian carcinoma (MOC) is a rare, chemoresistant tumor that shares pathologic features with tumors of the gastrointestinal and pancreaticobiliary tracts and remains clinically, morphologically, and epidemiologically distinct from other more common ovarian cancer histologic subtypes. MOC accounts for 1-8% of all ovarian, typically affecting younger women and has a poor prognosis when disease has spread beyond the ovary. Unlike other epithelial ovarian cancers, increased risk of MOC is associated with cigarette smoking in a dose-dependent fashion. Oral contraceptive use that has been shown to be protective in serous ovarian cancer does not extend to MOCs. Despite clinical, pathologic, and epidemiologic differences from other epithelial ovarian cancers, MOC treatment continues to use standards defined for high grade serous ovarian cancer including comprehensive surgical staging followed by platinum and taxane combination chemotherapy for disease spread beyond the ovary. Most mucinous adenocarcinomas that involve the ovary are now recognized to be metastatic disease from an extraovarian site, most commonly gastrointestinal and pancreatic. In advanced stage cases, defining clear diagnostic criteria that reliably differentiates primary versus malignant tumors remains a challenge. Despite a similar site of origin, the molecular profile of MOC has few similarities to high-grade serous ovarian carcinoma, which is characterized by ubiquitous TP53 mutations, frequent BRCA1/2 mutations, and few KRAS mutations. The mutational landscape of MOC is characterized by frequent KRAS, TP53, ARID1A, and PIK3CA mutations as well as frequent CDKN2A homozygous deletions. Co-mutations of KRAS and TP53 are common. New data describe the molecular features of MOC using an integrative and comprehensive approach including next-generation sequencing, copy number analysis and immunohistochemistry that may lead to expanded treatment options for women with this rare disease. Data suggest a shared molecular pattern with pancreatic adenocarcinoma that may guide future therapeutics. Citation Format: Douglas A. Levine, Brooke Schlappe. Molecular characterization of mucinous ovarian carcinoma. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr IA17.
Psychological microbes
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The incidence of toxic shock syndrome in Northern California. 1972 through 1983
Authors: D. B. Petitti
Journal: JAMA (1986)

In its 1982 report on toxic shock syndrome, the Institute of Medicine, Washington, DC, identified population-based studies of the incidence of toxic shock syndrome over time based on hospital records as being a high priority for further research. We conducted such a study using records of hospitalizations in Northern California Kaiser-Permanente Medical Care Program facilities for the period from 1972 through 1983 among women and men aged 15 through 34 for illnesses considered possibly to be toxic shock syndrome. Of 6,688 hospitalizations reviewed, 54 were considered definite cases of toxic shock syndrome, and an additional nine were considered probable toxic shock syndrome. Four definite cases of toxic shock syndrome occurred in men, and 50 in women. The overall incidence of definite hospitalized toxic shock syndrome in men was 0.1 per 100,000 person-years, and in women 1.5 per 100,000 person-years. In women, an increase in the incidence of toxic shock syndrome was apparent by 1977; the rate peaked in 1980, decreased slightly in 1981 and 1982, and then almost doubled again in 1983. The temporal trend in the incidence of hospitalized toxic shock syndrome in women in the years 1977 through 1982 is consistent with the best available information on patterns of use of tampons containing higher-absorbency materials. The sharp increase in the incidence of hospitalized toxic shock syndrome in 1983 remains unexplained. (<i>JAMA</i>1986;255:368-372)
Some German Spas. A Holiday Record.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Journal of Medical Education, Chicago
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ABSTRACTS
Authors: Ernst Jaff, # {233}, York City, Michel Jamra, Alan Johnson, Oliver Jones, Joseph Kassirsky, U Sven-Age, E Kowalski, E Loeliger, The Netherlands, Cohn Macpherson, H Martin, Bracha Ramot, Tel Aviv, Peter Reizenstein, Richard Rosenfield, N Dioguardi, A Agostoni, C Fiorelli, B Lomanto
Journal: Blood (1964)
Metastatic Calcification in a Patient with Malignant Parathyroid Carcinoma
Authors: ROBERT M. DAVIDSON, RAMESH D. DHEKNE, WARREN H. MOORE, DONALD B. BUTLER
Journal: Clinical Nuclear Medicine (1990)

DAVIDSON, ROBERT M. M.D*; DHEKNE, RAMESH D. M.D*; MOORE, WARREN H. M.D*; BUTLER, DONALD B. M.D.† Author Information
"Turner phenotypes" vs Noonan's syndrome
Authors: F. Char
Journal: JAMA (1971)

<h3>To the Editor.—</h3> Chapman raised a fascinating question: How well can the future be predicted on ecological reasoning, and what should we do about it? Apart from the usual pitfalls of prediction, he pointed out a sentimental tendency of conservationists to feel that "Nature knows best," or laissez faire. Unless we adopt the dangerous thesis that man is somehow separate from the rest of life, consistency requires us to let nature regulate everything. This seems to mean that we do nothing at all. The author noted in passing that ecological balances are never really stable, subject as they are to vagaries of climate and geology (not to mention biological evolution). Even against this background, however, our species has broken every rule in the book. Since the appearance of man, ecological instability has gone up by several orders of magnitude and is still rising. It has become evident since 1950, that
381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Authors: D.S. Hong, Y-J. Bang, F. Barlesi, G. Durm, G.S. Falchook, R. Govindan, G.K. Dy, K. Park, J.H. Strickler, T.F. Burns, J. Kim, A. Ang, J.R. Lipford, G. Ngarmchamnanrith, A. Anderson, B.T. Li
Journal: Annals of Oncology (2020)
Chronic Obstructive Pulmonary Disease
Authors: Richard A. Mularski
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA Internal Medicine (2019)

Representativeness of RCT Cohorts in Kidney Disease 1316Smyth and colleagues performed this meta-analysis to determine if participants in large, multicenter dialysis randomized clinical trials (RCTs) were similar to the general population undergoing dialysis in terms of age, comorbidities, and mortality rate.A total of 189 trials, including 80 104 participants, were identified after searching 3 major databases across a 10-year period.Results demonstrated that trial participants were significantly younger, more likely to be male, and less likely to have diabetes or diabetic nephropathy than patients in the US national registry.Moreover, the mortality rate of dialysis-dependent patients recruited to large, multicenter RCTs was substantially lower than that of registry patients, both overall and when only studies recruiting participants from the United States were considered.Ross and Covinsky provide the Editor's Note.
Experimental practices in economics: A methodological challenge for psychologists?
Authors: Ralph Hertwig, Andreas Ortmann
Journal: Behavioral and Brain Sciences (2001)

This target article is concerned with the implications of the surprisingly different experimental practices in economics and in areas of psychology relevant to both economists and psychologists, such as behavioral decision making. We consider four features of experimentation in economics, namely, script enactment, repeated trials, performance-based monetary payments, and the proscription against deception, and compare them to experimental practices in psychology, primarily in the area of behavioral decision making. Whereas economists bring a precisely defined “script” to experiments for participants to enact, psychologists often do not provide such a script, leaving participants to infer what choices the situation affords. By often using repeated experimental trials, economists allow participants to learn about the task and the environment; psychologists typically do not. Economists generally pay participants on the basis of clearly defined performance criteria; psychologists usually pay a flat fee or grant a fixed amount of course credit. Economists virtually never deceive participants; psychologists, especially in some areas of inquiry, often do. We argue that experimental standards in economics are regulatory in that they allow for little variation between the experimental practices of individual researchers. The experimental standards in psychology, by contrast, are comparatively laissez-faire. We believe that the wider range of experimental practices in psychology reflects a lack of procedural regularity that may contribute to the variability of empirical findings in the research fields under consideration. We conclude with a call for more research on the consequences of methodological preferences, such as the use on monetary payments, and propose a “do-it-both-ways” rule regarding the enactment of scripts, repetition of trials, and performance-based monetary payments. We also argue, on pragmatic grounds, that the default practice should be not to deceive participants.
Rhinoscleroma
Authors: Max A. Goldzieher
Journal: JAMA (1965)

<h3>To the Editor:—</h3> Your editorial on rhinoscleroma (<i>JAMA</i><b>190</b>:847 [Nov 30] 1964) voices doubts about the etiological role of the bacilli found in the cells of the diseased tissue. May I call your attention to a paper which I published in 1909 together with Dr. E. Neuber in the Centralblatt fúr Bacteriologie (<b>51</b>: 121) about rhinoscleroma. In this extensive study we showed that the patient's serum gave a positive complement fixation with extracts of bacterial cultures from the patient in question and of other cultures. The complement fixation succeeded in distinguishing the "rhinoscleroma bacillus" from what was then called the Friedlander group. The pathogenic role of the bacillus was emphasized furthermore by the fact that the complement fixation of the patient's serum became negative after the x-ray treatment produced a complete regression of the patient's lesions.
ADENOMYOMATA OF THE FEMALE SEXUAL APPARATUS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Education about drug abuse in medical schools
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EPHA2 receptor is involved in in vivo acquired resistance to anti-epidermal growth factor receptor (EGFR) treatment in metastatic colorectal cancer
Authors: G. Martini, V. Belli, P.P. Vitiello, T. Troiani, C. Cardone, S. Napolitano, N. Matrone, V. Sforza, B. Savastano, F. Renato, F. Morgillo, C.M. Della Corte, D. Ciardiello, E.F. Giunta, V. De Falco, N. Zanaletti, P. Vitale, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2017)